Use of statins in the elderly

Mechanism: statins inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptors. Beyond LDL lowering they have pleiotropic effects — plaque stabilisation, reduced inflammation and improved endothelial function. Three of four acute myocardial infarcts are thought to arise from rupture or erosion of a vulnerable plaque, which statins stabilise.

Secondary prevention — strong evidence at all ages. The Cholesterol Treatment Trialists' meta-analysis of 28 randomised trials showed significant benefit in patients with established vascular disease in every age group, including those over 75. Key trials in older patients: PROSPER (pravastatin 40 mg, age 70–82, 34% LDL reduction, RR 0.85 for cardiovascular events), HPS (simvastatin 40 mg) and LIPS (fluvastatin after PCI).

Primary prevention — evidence is weaker with advancing age. The same meta-analysis showed a trend to smaller proportional risk reduction with increasing age, and no significant benefit in those over 70 without vascular disease. ALLHAT-LLT was neutral in older primary prevention.

Guideline position: ACC/AHA states it "may be reasonable" to initiate moderate-intensity statin in adults ≥75 with LDL-C 70–189 mg/dL; ESC/EAS says primary prevention statin "may be considered" over 75 if high risk (e.g. diabetes). Pathy's notes it may equally be reasonable not to prescribe.

Time-to-benefit and lag time are decisive in geriatrics: the time to benefit for statins in primary prevention is at least two years. If estimated life expectancy is shorter, the drug adds burden without benefit.

Adherence is poor in the elderly: only about one in four older patients is still taking a statin two years after prescription, and about 20% show primary non-adherence — never starting the prescribed drug at all.

Adverse effects: statin-associated muscle symptoms (myalgia with normal CK; myositis with CK <10× ULN; rhabdomyolysis with CK >10× ULN), hepatotoxicity (act if ALT/AST >3× ULN), a small increase in incident type 2 diabetes, and drug interactions through CYP3A4 (amiodarone, verapamil, diltiazem, clarithromycin, azoles) which are especially relevant with polypharmacy. Concerns about cognitive impairment are not supported by good evidence.

Practical monitoring: check baseline lipids, ALT/AST, CK, TSH and renal function; recheck lipids and transaminases after 8–12 weeks. In statin-associated muscle symptoms with CK <10× ULN, reduce the dose or rechallenge with an alternative statin; if CK >10× ULN, stop the statin and check creatinine, urea and myoglobinuria. Persistent symptoms with rising CK should prompt testing for anti-HMG-CoA reductase antibodies (immune-mediated necrotising myopathy) or muscle biopsy.

Intensity and add-ons: high-intensity statins lower LDL-C by 50–55%; adding ezetimibe gives a further 20% reduction. In very high-risk atherosclerotic disease with LDL-C ≥70 mg/dL on maximal statin, ezetimibe then a PCSK9 inhibitor may be added.

Decision framework for the older patient: continue statins for secondary prevention unless life expectancy is very short; for primary prevention over 75 use shared decision-making weighing benefit against polypharmacy, frailty, life expectancy, adverse effects and the patient's own priorities. Deprescribing is appropriate in advanced frailty, end-stage disease or the last year of life. Latest Updates and Current Practice Update (concise) EWTOPIA 75 (Circulation 2019) showed benefit from ezetimibe monotherapy in Japanese patients ≥75 with LDL-C ≥140 mg/dL, and a 2020 Lancet meta-analysis (Gencer et al.) concluded that LDL lowering is beneficial in patients over 75 — a shift toward treating rather than withholding. STAREE (atorvastatin 40 mg versus placebo in 9,971 community-dwelling Australians aged ≥70 without cardiovascular disease, diabetes or dementia; co-primary endpoints of disability-free survival and major cardiovascular events) completed follow-up at the end of 2025. It is the definitive trial for primary prevention in this age group; its results should be quoted as soon as published. Newer non-statin agents now available for statin intolerance or residual risk: bempedoic acid (CLEAR Outcomes 2023 — reduced major cardiovascular events in statin-intolerant patients, with no muscle toxicity), inclisiran (twice-yearly siRNA, useful where adherence is the barrier), and PCSK9 monoclonal antibodies.